Diabetes News You Can Use
How muscle metabolism differs between women, men
A study in the journal Molecular Metabolism found that the skeletal muscles of men and women process glucose and fats differently, potentially explaining variations in how diabetes manifests and responds to physical activity between the sexes. Researchers found that initial endurance exercise triggered a stronger stress response in men’s muscles, while women’s muscles had a more efficient fat utilization. After eight weeks of regular training, these differences decreased, improving overall metabolic performance for both sexes.
Full Story: Medical Xpress (7/7)
More people considered obese under new definition
A 2024 framework from the European Association for the Study of Obesity that factors BMI and waist-to-height ratio into a definition of obesity classifies about 20% of people previously considered overweight as having obesity, according to a study in the Annals of Internal Medicine. The definition also takes into account obesity-related complications.
Full Story: Medscape (7/8)
No added thyroid tumor risk found with GLP-1 RAs
GLP-1 receptor agonist therapy does not increase the risk of thyroid tumors in people with type 2 diabetes, according to a study in the journal Diabetes Care. The retrospective study, which included data from several international databases, found no increased risk of both malignant and benign thyroid tumors with GLP-1 RAs compared with other second-line therapies.
Full Story: Endocrinology Advisor (7/7)
Dual-action drug shows promise for weight loss
Amycretin, an investigational drug targeting both GLP-1 and amylin receptors, has shown significant weight loss effects in early trials, with reductions of up to 24% with weekly injections and 13% with daily oral doses, according to a study in The Lancet. While promising, the drug, which also improved blood sugar regulation, was associated with gastrointestinal side effects that were mostly mild to moderate.
Full Story: Diabetes (UK) (7/5)
Weekly semaglutide and insulin noninferior to daily insulin
A Phase 3 trial in The Lancet Diabetes & Endocrinology found that a once-weekly combination of semaglutide and insulin icodec was noninferior to daily basal-bolus therapy in reducing A1C levels in patients with type 2 diabetes inadequately controlled with daily basal insulin. The treatment resulted in greater weight loss, lower weekly insulin doses and fewer hypoglycemic episodes.
Full Story: Medscape (7/2)
Groups call for lifestyle changes with GLP-1 use
A joint statement from several other health care organizations, published in the journal Obesity, emphasizes the importance of integrating diet, exercise and lifestyle modifications with the use of glucagon-like peptide-1 receptor agonists for obesity management. The statement highlighted the need for individualized care plans that address social determinants of health and barriers to medication access and lifestyle changes.
Full Story: Endocrinology Advisor (6/27)
Weight management may lower risk of type 2 diabetes
Research in the European Journal of Nutrition found that managing body weight is a key factor in reducing the risk of type 2 diabetes across different ethnic groups. The study, which included 165,383 participants from various backgrounds, found that those with a BMI over 30 were more than three times as likely to develop type 2 diabetes compared with those with a normal weight.
Full Story: Diabetes (UK) (6/27)
CGM may not improve outcomes with gestational diabetes
Real-time continuous glucose monitoring may not affect health outcomes for women with gestational diabetes, according to a study in The Lancet Diabetes and Endocrinology. The research compared continuous monitoring with self-monitoring of blood glucose in 302 women, finding no significant differences in obstetric or neonatal outcomes.
Full Story: Endocrinology Advisor (6/27)
Novo Nordisk ends Hims & Hers deal over Wegovy copycats
Novo Nordisk has terminated its partnership with Hims & Hers due to concerns over the telehealth company’s continued sales and promotion of compounded, unapproved versions of the weight-loss drug Wegovy. Novo Nordisk stated that Hims & Hers did not comply with legal restrictions that prohibit mass sales of compounded drugs after the end of the official Wegovy shortage, criticizing the company for deceptive marketing and prioritizing patient safety as the main reason for ending the collaboration.
Full Story: CNBC (6/23)
Diabetes Research Center
Related News
Congratulations to this year’s funding awardees
Congratulations to this year’s funding awardees: Dr. Nicholas Chavkin and Dr. Stephen McCartney have been awarded Pilot and Feasibility awards and Ms. Jocelyn Cervantes has been awarded the Stroum Graduate Fellowship award.
NIDDK 75th Anniversary
In celebration of the 75th anniversary of NIDDK, Diabetes Care and Diabetes have published a compendium of ten articles that highlight just a few of the major contributions NIIDK has fostered through its support of research. These articles provide a broad, but clearly not complete, view of the results that have been achieved through their fostering of science across the country. Included amongst these is a paper by members of NIDDK about the research centers including the Diabetes Research Centers Program. There is also an editorial that celebrates NIDDK and at the same times raises concerns about the future of research and public health related to diabetes given the current discussion about the funding and restructuring of NIDDK and CDC.
DRC Affiliate Edward Boyko is Co-Chair of New Diabetes Atlas
DRC affiliate, Edward Boyko, professor (General Internal Medicine) is co-chair of the new edition of the International Diabetes Federation (IDF) Diabetes Atlas. As the number of people living with diabetes continues to rise, the latest IDF Diabetes Atlas emphasizes the urgent need for improved prevention, early detection and intervention to tackle the burden diabetes places on individuals, communities, health systems and economies.
Learn more on our news site.
CVTMC Director Karin Bornfeldt Announced as 2025 American Society for Biochemistry and Molecular Biology Fellow
The American Society for Biochemistry and Molecular Biology (ASBMB) announced that CVTMC Director Karin Bornfeldt, professor (Metabolism, Endocrinology and Nutrition), has been named among its 2025 class of fellows. Designation as a fellow recognizes commitment to the ASBMB through a history of exceptional and sustained service to the society as well as impactful accomplishments in research, education, mentorship, and service to the scientific community. Twenty-four fellows were selected this year. Read more here.
Affiliate Anne Manicone receives Pilot Award
Affiliate Anne Manicone, professor (Pulmonary, Critical Care, and Sleep Medicine) received a Pilot Project Award, “Identifying Novel Compounds to Polarize Macrophages toward Reparative States,” from the parent P30 Grant, “Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era,” funded by NIH/NIDDK. This 2-year award will provide $264,000 towards developing new strategies to target chronic inflammation seen in people with Cystic Fibrosis.